Literature DB >> 16857724

Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine.

Paul S Fitzmaurice1, Junchao Tong, Mehrdad Yazdanpanah, Peter P Liu, Kathryn S Kalasinsky, Stephen J Kish.   

Abstract

Animal studies suggest that the widely used psychostimulant drug methamphetamine (MA) can harm brain dopamine neurones, possibly by causing oxidative damage. However, evidence of oxidative damage in brain of human MA users is lacking. We tested the hypothesis that levels of two "gold standard" products generated from lipid peroxidation, 4-hydroxynonenal (one of the most reactive lipid peroxidation aldehyde products) and malondialdehyde, would be elevated in post mortem brain of 16 dopamine-deficient chronic MA users compared with those in 21 matched control subjects. Derivatized aldehyde concentrations were determined by gas chromatography-mass spectrometry. In the MA group, we found significantly increased levels of 4-hydroxynonenal and malondialdehyde in the dopamine-rich caudate nucleus (by 67 and 75%, respectively) and to a lesser extent in frontal cortex (48 and 36%, respectively) but not in the cerebellar cortex. Approximately half of the MA users had levels of 4-hydroxynonenal falling above the upper limit of the control range in caudate and frontal cortex. A subgroup of MA users with high brain drug levels had higher concentrations of the aldehydes. Our data suggest that MA exposure in human causes, as in experimental animals, above-normal formation of potentially toxic lipid peroxidation products in brain. This provides evidence for involvement of oxygen-based free radicals in the action of MA in both dopamine-rich (caudate) and -poor (cerebral cortex) areas of human brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857724     DOI: 10.1124/jpet.106.109173

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

1.  Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease.

Authors:  M A Bradley; W R Markesbery; M A Lovell
Journal:  Free Radic Biol Med       Date:  2010-02-18       Impact factor: 7.376

2.  N-Acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells.

Authors:  Xinsheng Zhang; Atrayee Banerjee; William A Banks; Nuran Ercal
Journal:  Brain Res       Date:  2009-04-15       Impact factor: 3.252

Review 3.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 4.  Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review.

Authors:  Eun-Joo Shin; Hai-Quyen Tran; Phuong-Tram Nguyen; Ji Hoon Jeong; Seung-Yeol Nah; Choon-Gon Jang; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

Review 5.  Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies.

Authors:  Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis
Journal:  Pharmacol Biochem Behav       Date:  2019-01-26       Impact factor: 3.533

6.  The role of reactive oxygen species in methamphetamine self-administration and dopamine release in the nucleus accumbens.

Authors:  Eun Young Jang; Chae Ha Yang; David M Hedges; Soo Phil Kim; Jun Yeon Lee; Tyler G Ekins; Brandon T Garcia; Hee Young Kim; Ashley C Nelson; Nam Jun Kim; Scott C Steffensen
Journal:  Addict Biol       Date:  2016-07-14       Impact factor: 4.280

7.  Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cδ gene.

Authors:  Eun-Joo Shin; Seung Woo Shin; Thuy-Ty Lan Nguyen; Dae Hun Park; Myung-Bok Wie; Choon-Gon Jang; Seung-Yeol Nah; Byung Wook Yang; Sung Kwon Ko; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Mol Neurobiol       Date:  2014-01-16       Impact factor: 5.590

8.  PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and ( --)-cocaine.

Authors:  Joanna S Fowler; Carsten Kroll; Richard Ferrieri; David Alexoff; Jean Logan; Stephen L Dewey; Wynne Schiffer; David Schlyer; Pauline Carter; Payton King; Colleen Shea; Youwen Xu; Lisa Muench; Helene Benveniste; Paul Vaska; Nora D Volkow
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

9.  Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine.

Authors:  Joanna S Fowler; Nora D Volkow; Jean Logan; David Alexoff; Frank Telang; Gene-Jack Wang; Christopher Wong; Yeming Ma; Aarti Kriplani; Kith Pradhan; David Schlyer; Millard Jayne; Barbara Hubbard; Pauline Carter; Donald Warner; Payton King; Colleen Shea; Youwen Xu; Lisa Muench; Karen Apelskog
Journal:  Neuroimage       Date:  2008-07-22       Impact factor: 6.556

10.  Adaptation of brain glutamate plus glutamine during abstinence from chronic methamphetamine use.

Authors:  Thomas Ernst; Linda Chang
Journal:  J Neuroimmune Pharmacol       Date:  2008-06-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.